Melane Sampson, Author at BioTuesdays

Developments

BiomX reports update on trial of BX004 in CF

BiomX (NYSE American: PHGE) has announced that the FDA is continuing its evaluation of the nebulizer device used for drug administration in the company’s Phase 2b trial of BX004 in patients with cystic fibrosis (CF)...

November 26, 2025

Developments

Ripple enters into a collaboration with Bausch + Lomb

Closely held Ripple Therapeutics has announced that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb (NYSE/TSX: BLCO). Under the terms of the...

November 25, 2025

Developments

Clearmind’s DSMB recommends continuation of trial for CMND-100 in AUD; patient enrollment at TASMC kicks off

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that its independent Data and Safety Monitoring Board (DSMB) has completed a scheduled interim review of its ongoing FDA-approved multinational Phase I/IIa...

November 25, 2025

Developments

PetVivo launches AI platform reducing vet client acquisition costs by 50-89%

PetVivo Holdings (OTCQX: PETV; OTCID: PETVW) has announced the launch of PetVivo.ai that delivers a veterinary client acquisition cost of $42.53—a 50% to 89% reduction compared to $80 to $400 typically spent by...

November 25, 2025

Feature

Trevi reinventing chronic cough treatment with a dual-action approach to hypersensitivity

Trevi Therapeutics (NASDAQ: TRVI) is advancing a fundamentally different approach to the treatment of chronic cough—a high unmet need that significantly affects the quality of life for millions of Americans.

November 25, 2025

Developments

Psyence reports major breakthrough in establishing pharmaceutical-grade ibogaine supply

Psyence BioMedical (NASDAQ: BPM) has announced it has sourced a sustainable supply of high-potency iboga bark—through its strategic partner, closely held PsyLabs—a significant achievement as the company prepares for the...

November 20, 2025

Developments

OS to spin off OSAH into a standalone company

OS Therapies (NYSE American: OSTX) has announced its intent to spin off OS Animal Health (OSAH)—the company’s wholly owned subsidiary developing OST-HER2 for canine osteosarcoma—into a standalone public company...

November 20, 2025

Developments

Profound celebrates The Hong Center’s 200th independent TULSA procedure; Dr. Mark Hong sees TULSA ultimately replacing radical prostatectomy as a first-line option for prostate cancer

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced today that The Hong Center Scottsdale, led by Dr. Y. Mark Hong of Integrative Urology in Phoenix, Arizona, has achieved a world-first milestone: 200 TULSA...

November 18, 2025

Developments

Quanterix highlights landmark study published in Brain validating dual approach for personalized MS monitoring

Quanterix (NASDAQ: QTRX) has announced the publication of a landmark study in the peer-reviewed scientific journal Brain, validating that multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and...

November 18, 2025

Developments

Modular receives IRB approval to deliver insulin via Pivot patch pump

Modular Medical (NASDAQ: MODD) has announced that the Institutional Review Board (IRB) has granted approval to conduct an in-house study of its next-generation Pivot insulin delivery system using insulin on people with...

November 17, 2025

Author - Melane Sampson

BiomX reports update on trial of BX004 in CF

Ripple enters into a collaboration with Bausch + Lomb

Clearmind’s DSMB recommends continuation of trial for CMND-100 in AUD; patient enrollment at TASMC kicks off

PetVivo launches AI platform reducing vet client acquisition costs by 50-89%

Trevi reinventing chronic cough treatment with a dual-action approach to hypersensitivity

Psyence reports major breakthrough in establishing pharmaceutical-grade ibogaine supply

OS to spin off OSAH into a standalone company

Profound celebrates The Hong Center’s 200th independent TULSA procedure; Dr. Mark Hong sees TULSA ultimately replacing radical prostatectomy as a first-line option for prostate cancer

Quanterix highlights landmark study published in Brain validating dual approach for personalized MS monitoring

Modular receives IRB approval to deliver insulin via Pivot patch pump

Subscribe